S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Avoro Capital Advisors/Q2 2025

Avoro Capital Advisors

Period: Q2 2025 Β· Filed: 2025-08-14
View on SEC EDGAR β†—
AUM
$5.71B
Total portfolio value
Positions
30
Reported securities
Top Holding
ASND
15.1% $859.5M
QoQ Changes
+1 / -4
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-08-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ASNDASCENDIS PHARMA$859.5M15.05%$172.60$274.50+59.0%
15.1%
UTHRUNITED THERAPEUTICS CORP$681.0M11.93%$287.35$555.91+93.5%
11.9%
ARGXARGENX SE$647.7M11.34%$551.22$939.68+70.5%
11.3%
MDGLMADRIGAL PHARMACEUTICALS INC$567.5M9.94%$302.64$528.10+74.5%
9.9%
KRYSKRYSTAL BIOTECH INC$365.6M6.40%$137.46$375.07+172.9%
6.4%
KYMRKYMERA THERAPEUTICS INC$286.1M5.01%$43.64$113.51+160.1%
5.0%
APLSAPELLIS PHARMACEUTICALS INC.$211.6M3.71%$17.31β€”
3.7%
RNAMAVIDITY BIOSCIENCES INC$200.2M3.51%β€”β€”
3.5%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$195.9M3.43%$47.20$18.95-59.9%
3.4%
AKROAKERO THERAPEUTICS INC$186.8M3.27%β€”β€”
3.3%
SLNOSOLENO THERAPEUTICS INC$171.8M3.01%$83.78β€”
3.0%
XENEXENON PHARMACEUTICALS INC$169.0M2.96%$31.30$60.96+94.8%
3.0%
ARWRARROWHEAD PHARMACEUTICALS INC.$167.5M2.93%$15.80$83.99+431.6%
2.9%
MRUSMERUS N V$166.0M2.91%β€”β€”
2.9%
VERAVERA THERAPEUTICS INC$148.4M2.60%$23.56$41.20+74.9%
2.6%
FOLDAMICUS THERAPEUTICS INC.$103.1M1.81%β€”β€”
1.8%
ALKSALKERMES PLC$83.0M1.45%$28.61$54.58+90.8%
1.4%
OCULOCULAR THERAPEUTIX INC$68.7M1.20%$9.28$9.64+3.9%
1.2%
ETNB89BIO INC$66.3M1.16%β€”β€”
1.2%
CNTACENTESSA PHARMACEUTICALS PLC$65.7M1.15%$13.14$40.50+208.2%
1.1%
QUREUNIQURE NV$50.5M0.88%$13.94$41.81+199.9%
0.9%
TSHATAYSHA GENE THERAPIES INC$50.1M0.88%$2.31$6.53+182.7%
0.9%
BPMCBLUEPRINT MEDICINES CORP$48.1M0.84%β€”β€”
0.8%
TRMLTOURMALINE BIO INC$40.9M0.72%β€”β€”
0.7%
BCRXBIOCRYST PHARMACEUTICALS INC$40.3M0.71%$8.96$9.84+9.8%
0.7%
MNKDMANNKIND CORP$21.9M0.38%$3.74$4.52+20.9%
0.4%
GLUEMONTE ROSA THERAPEUTICS INC$16.8M0.29%$4.51$24.21+436.8%
0.3%
SEPNSEPTERNA INC$13.1M0.23%$10.57$34.00+221.7%
0.2%
RAREULTRAGENYX PHARMACEUTICAL INC$12.0M0.21%$36.36$33.47-8.0%
0.2%
WHWKWHITEHAWK THERAPEUTICS INC$5.3M0.09%$1.87$4.19+124.1%
0.1%

Quarter-on-Quarter Activity

Q2 2025 vs. Q1 2025

New Positions (1)

TickerIssuerNotional
AKROAKERO THERAPEUTICS INC$186.8M

Exited Positions (4)

TickerIssuerNotional
SRPTSAREPTA THERAPEUTICS INC$170.7M
ITCIINTRA-CELLULAR THERAPIES INC$82.5M
PCVXVAXCYTE INC$37.8M
AUTLAUTOLUS THERAPEUTICS PLC$15.4M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
QUREUNIQURE NV$27.5M+66.7%+199.9%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$87.7M+49.8%-59.9%
CNTACENTESSA PHARMACEUTICALS PLC$7.5M+23.5%+208.2%
ALKSALKERMES PLC$2.1M+18.4%+90.8%
VERAVERA THERAPEUTICS INC$11.5M+10.5%+74.9%
TSHATAYSHA GENE THERAPIES INC$22.3M+8.5%+182.7%
ETNB89BIO INC$20.1M+6.3%
TRMLTOURMALINE BIO INC$4.0M+5.4%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
BPMCBLUEPRINT MEDICINES CORP$-292.7M-90.3%
RAREULTRAGENYX PHARMACEUTICAL INC$-18.1M-60.2%-8.0%
BCRXBIOCRYST PHARMACEUTICALS INC$-24.9M-48.3%+9.8%
MNKDMANNKIND CORP$-22.1M-33.1%+20.9%
GLUEMONTE ROSA THERAPEUTICS INC$-4.8M-19.8%+436.8%
SLNOSOLENO THERAPEUTICS INC$-8.7M-18.8%
FOLDAMICUS THERAPEUTICS INC.$-64.1M-12.2%
UTHRUNITED THERAPEUTICS CORP$-143.6M-11.4%+93.5%
← Back to Hedge Funds